Latest news with #StockWatch
Newsweek
13-06-2025
- Sport
- Newsweek
Yankees Linked to Eugenio Suarez in Blockbuster Trade
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. The New York Yankees are approaching July's trade deadline as one of MLB's best teams. They have an offense led by Aaron Judge, a heavy American League MVP favorite who could just win the Triple Crown. They have a strong top of the starting rotation, with Max Fried leading the way and Carlos Rodon having an unbelievable bounce back season. More news: Yankees Pitcher Appears to Have UCL Injury in Concerning Development And while the bullpen has been inconsistent, Luke Weaver is set to return sometime next month and Devin Williams has been much better as of late. This year's Yankees team — even without Juan Soto (signed with the New York Mets) and Gerrit Cole (underwent Tommy John surgery) — may be even better than the 2024 version that went to the World Series. However, there are a few clear holes that need to be addressed ahead of the trade deadline, and there may be no bigger one than third base. While the Yankees have tried to address that problem by moving Jazz Chisholm to third base, that then leaves a hole at second base, where Chisholm is a more natural and superior defender anyway. Thus, the Yankees should look to add a third baseman at the deadline, and ESPN's Brad Doolittle has just the idea: Arizona Diamondbacks third baseman Eugenio Suarez. NEW YORK, NEW YORK - APRIL 01: Pavin Smith #26, Corbin Carroll #7 and Eugenio Suárez #28 of the Arizona Diamondbacks celebrate after Suárez drove them in with a grand slam in the eighth inning... NEW YORK, NEW YORK - APRIL 01: Pavin Smith #26, Corbin Carroll #7 and Eugenio Suárez #28 of the Arizona Diamondbacks celebrate after Suárez drove them in with a grand slam in the eighth inning against the New York Yankees at Yankee Stadium on April 01, 2025 in the Bronx borough of New York what Doolittle had to say while discussing what New York should do at the deadline. "First, note the Yankees' title odds, which are the highest in this month's Stock Watch. New York has a higher baseline rating than Detroit, giving the Yankees a narrow edge in all those simulated AL Championship Series meetings with the Tigers despite the road disadvantage. Also, the postseason paths of New York and Detroit are less laden with superteams than their NL brethren, so -- voilà! -- the Yankees' title odds are looking good. To stay there: They need more pitching for sure, though the Yankees have done a great job of piecing things together so far. A more impactful pickup might come from a power bat for third base, with Arizona's Eugenio Suarez leaping to mind as an ideal fit." Suarez, 33, is having another strong season at the plate, slashing .233/.305/.514 with 19 home runs, 52 RBIs and an OPS of .819. The one-time All-Star has had at least 30 home runs in three of the past four seasons, and set a career-high with 49 home runs back in 2019. More news: Braves Veteran Slams Organization for Craig Kimbrel Decision While Suarez is a below average defender, he more than makes up for it with his slugging. He would be a significant upgrade for the Yankees at third base, where they've received a total production of 0.0 fWAR. Suarez, on the other hand, has generated 1.2 fWAR by himself. Finally, Suarez is on an expiring deal, as Arizona picked up his $15 million club option after playing out his seven-year, $66 million deal. Thus, he shouldn't cost New York too much for half a season of production, and his bat could be the difference in a short postseason series. In eight career postseason games, Suarez has an OPS of .810. For more MLB news, head over to Newsweek Sports.
Associated Press
04-05-2025
- Business
- Associated Press
TMCI Investors are Urged to Contact Robbins LLP for Information About the Treace Medical Concepts, Inc. Class Action Lawsuit
SAN DIEGO, CA - May 3, 2025 ( NEWMEDIAWIRE ) - Robbins LLP reminds stockholders that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Treace Medical Concepts, Inc. (NASDAQ: TMCI) securities between May 8, 2023 and May 7, 2024. The Company is focused on advancing the standard of care for the surgical management of bunion and related midfoot deformities. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that Treace Medical Concepts, Inc. (TMCI) Misled Investors Regarding Demand for its Primary Product According to the complaint, during the class period, defendants failed to disclose that (1) competition impacted the demand for and utilization of its primary product, the Lapiplasty 3D Bunion Correction System, and (2) as a result, Treace Medical's revenue declined and the Company needed to accelerate its plans to offer a product that was an alternative to osteotomy (a surgical procedure that involves cutting and realigning a bone to improve its position or function). Plaintiff alleges that when the truth was revealed, the price of Treace Medical's stock fell nearly 63%, to close at $4.17 per share on May 8, 2024. What Now: You may be eligible to participate in the class action against Treace Medical Concepts, Inc. Shareholders who want to serve as lead plaintiff for the class must file their papers with the court by June 10, 2025. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Treace Medical Concepts, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today. Attorney Advertising. Past results do not guarantee a similar outcome. Contact: Aaron Dumas, Jr. Robbins LLP 5060 Shoreham Pl., Ste. 300 San Diego, CA 92122 [email protected] (800) 350-6003
Associated Press
02-05-2025
- Business
- Associated Press
Treace Medical Concepts, Inc. Stock News: Shareholder Rights Law firm Robbins LLP Reminds TMCI Stockholders of the Securities Fraud Class Action
SAN DIEGO, CA - May 1, 2025 ( NEWMEDIAWIRE ) - Robbins LLP reminds stockholders that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Treace Medical Concepts, Inc. (NASDAQ: TMCI) securities between May 8, 2023 and May 7, 2024. The Company is focused on advancing the standard of care for the surgical management of bunion and related midfoot deformities. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that Treace Medical Concepts, Inc. (TMCI) Misled Investors Regarding Demand for its Primary Product According to the complaint, during the class period, defendants failed to disclose that (1) competition impacted the demand for and utilization of its primary product, the Lapiplasty 3D Bunion Correction System, and (2) as a result, Treace Medical's revenue declined and the Company needed to accelerate its plans to offer a product that was an alternative to osteotomy (a surgical procedure that involves cutting and realigning a bone to improve its position or function). Plaintiff alleges that when the truth was revealed, the price of Treace Medical's stock fell nearly 63%, to close at $4.17 per share on May 8, 2024. What Now: You may be eligible to participate in the class action against Treace Medical Concepts, Inc. Shareholders who want to serve as lead plaintiff for the class must file their papers with the court by June 10, 2025. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Treace Medical Concepts, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today. Attorney Advertising. Past results do not guarantee a similar outcome. Contact: Aaron Dumas, Jr. Robbins LLP 5060 Shoreham Pl., Ste. 300 San Diego, CA 92122 [email protected] (800) 350-6003 View the original release on
Associated Press
30-04-2025
- Business
- Associated Press
Robbins LLP Reminds TMCI Investors of the Opportunity to Lead the Class Action Against Treace Medical Concepts, Inc.
SAN DIEGO, CA - April 29, 2025 ( NEWMEDIAWIRE ) - Robbins LLP reminds stockholders that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Treace Medical Concepts, Inc. (NASDAQ: TMCI) securities between May 8, 2023 and May 7, 2024. The Company is focused on advancing the standard of care for the surgical management of bunion and related midfoot deformities. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that Treace Medical Concepts, Inc. (TMCI) Misled Investors Regarding Demand for its Primary Product According to the complaint, during the class period, defendants failed to disclose that (1) competition impacted the demand for and utilization of its primary product, the Lapiplasty 3D Bunion Correction System, and (2) as a result, Treace Medical's revenue declined and the Company needed to accelerate its plans to offer a product that was an alternative to osteotomy (a surgical procedure that involves cutting and realigning a bone to improve its position or function). Plaintiff alleges that when the truth was revealed, the price of Treace Medical's stock fell nearly 63%, to close at $4.17 per share on May 8, 2024. What Now: You may be eligible to participate in the class action against Treace Medical Concepts, Inc. Shareholders who want to serve as lead plaintiff for the class must file their papers with the court by June 10, 2025. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Treace Medical Concepts, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today. Attorney Advertising. Past results do not guarantee a similar outcome. Contact: Aaron Dumas, Jr. Robbins LLP 5060 Shoreham Pl., Ste. 300 San Diego, CA 92122 [email protected] (800) 350-6003 View the original release on
Malaysian Reserve
23-04-2025
- Business
- Malaysian Reserve
Contact Robbins LLP for Information About Leading the Treace Medical Concepts, Inc. Class Action Lawsuit
SAN DIEGO, April 23, 2025 /PRNewswire/ — Robbins LLP reminds stockholders that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Treace Medical Concepts, Inc. (NASDAQ: TMCI) securities between May 8, 2023 and May 7, 2024. The Company is focused on advancing the standard of care for the surgical management of bunion and related midfoot deformities. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that Treace Medical Concepts, Inc. (TMCI) Misled Investors Regarding Demand for its Primary Product According to the complaint, during the class period, defendants failed to disclose that (1) competition impacted the demand for and utilization of its primary product, the Lapiplasty 3D Bunion Correction System, and (2) as a result, Treace Medical's revenue declined and the Company needed to accelerate its plans to offer a product that was an alternative to osteotomy (a surgical procedure that involves cutting and realigning a bone to improve its position or function). Plaintiff alleges that when the truth was revealed, the price of Treace Medical's stock fell nearly 63%, to close at $4.17 per share on May 8, 2024. What Now: You may be eligible to participate in the class action against Treace Medical Concepts, Inc. Shareholders who want to serve as lead plaintiff for the class must file their papers with the court by June 10, 2025. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Treace Medical Concepts, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today. Attorney Advertising. Past results do not guarantee a similar outcome.
